Clearview Wealth Advisors’s Gilead Sciences GILD Stock Holding History

Clearview Wealth Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,378	Closed	-$321K	–	104
2024 Q1	$321K	Sell	4,378 -5,933	-58%	-$456K	0.33%	83
2023 Q4	$835K	Sell	10,311 -141	-1%	-$11K	0.97%	33
2023 Q3	$783K	Buy	10,452 +10,326	+8,195%	+$794K	0.97%	34
2023 Q2	$9.73K	Hold	126	–	–	0.01%	366
2023 Q1	$10.5K	Hold	126	–	–	0.01%	361
2022 Q4	$10.8K	Hold	126	–	–	0.01%	317
2022 Q3	$8K	Hold	126	–	–	0.01%	359
2022 Q2	$8K	Hold	126	–	–	0.01%	386
2022 Q1	$8K	Hold	126	–	–	0.01%	412
2021 Q4	$9K	Sell	126 -116	-48%	-$7.99K	0.01%	434
2021 Q3	$17K	Hold	242	–	–	0.01%	359
2021 Q2	$17K	Hold	242	–	–	0.01%	358
2021 Q1	$16K	Hold	242	–	–	0.01%	359
2020 Q4	$14K	Buy	+242	New	+$14.6K	0.01%	336

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clearview Wealth Advisors's GILD Position: Q2 2024 in Review

Clearview Wealth Advisors sold out of Gilead Sciences (GILD) in Q2 2024, closing a stake of 4,378 shares — an estimated $321K sold.

Clearview Wealth Advisors first reported a position in GILD in Q4 2020 and held it in 14 quarters. The position peaked at $835K in Q4 2023. 1,678 funds tracked by Wall St. Rank hold GILD as of Q2 2024.

Clearview Wealth Advisors reported no remaining Gilead Sciences position as of Q2 2024 after selling out during the quarter.
Clearview Wealth Advisors sold 4,378 Gilead Sciences shares in Q2 2024, an estimated $321K.
Clearview Wealth Advisors first reported a position in Gilead Sciences in Q4 2020 and held it in 14 quarters.
Clearview Wealth Advisors's Gilead Sciences position peaked at $835K in Q4 2023.
1,678 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2024.

Based on Clearview Wealth Advisors's 13F filing for Q2 2024, filed 1 Aug 2024.